BioSpace News Archive

Asensus Surgical, Inc. announced that Shameze Rampertab, Executive Vice President and Chief Financial Officer, will participate in the H. C. Wainwright Global Investment Conference in Miami, Florida.

KemPharm, Inc. (NasdaqGS: KMPH) (KemPharm, or the Company), a specialty pharmaceutical company focused on the discovery and development of novel treatments for rare central nervous system (CNS) diseases, today announced that members of management will participate in three upcoming in-person investor conferences.

BrainsWay Ltd. a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today reported first quarter 2022 financial results and provided an operational update.

Spero Therapeutics, Inc. announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the 2022 RBC Capital Markets Global Healthcare Conference and the H.C. Wainwright Global Investment Conference, which are taking place May 17-18 and May 23-25, respectively.

Iterum Therapeutics plc announced it met with the US Food and Drug Administration on May 5, 2022, to discuss its proposed plan to conduct one additional Phase 3 clinical trial to support the potential resubmission of the Company’s new drug application for oral sulopenem etzadroxil-probenecid for the treatment of uncomplicated urinary tract infections.

CymaBay Therapeutics, Inc. (NASDAQ: CBAY), today announced that multiple Phase 2 and Phase 3 study presentations on seladelpar, the first delpar currently in development for the treatment of PBC, will be delivered during Digestive Disease Week® (DDW) May 21 – 24.

GLC Medical Inc. is pleased to announce that it has completed the development of its GLCM Biosensor Test Platform, which produces results in under one-minute.

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and operating results for the first quarter ended March 31, 2022.

Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced financial results for the first quarter ended March 31, 2022 and provided an overview of recent developments.

PharmAbcine Inc. announced that Dr. Jin-San Yoo, Chairman and Chief Executive Officer of PharmAbcine is invited to participate at Jefferies Global Healthcare Conference over June 8-10, 2022 in New York, NY.